# Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler

> **NCT01213849** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 24 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone furoate 50 mcg (4 inhalations)
- **DRUG:** Fluticasone furoate 100 mcg (4 inhalations)
- **DRUG:** Fluticasone furoate 200 mcg (4 inhalations)
- **DRUG:** Vilanterol 25 mcg (4 inhalations)

## Key facts

- **NCT ID:** NCT01213849
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-04
- **Primary completion:** 2010-11-25
- **Final completion:** 2010-11-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213849, "Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01213849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*